Bioventus

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royal Philips

RadNet

We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.

3 Value Medical Stocks to Buy for Safety Amid Market Volatility

DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET.

Bioventus to Present at the Cantor Global Healthcare Conference

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET.

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Amarin Corporation Plc

CommScope Hld

1847 Holdings LLC

Gannett Co.

FiscalNote Holdings Inc

Precigen

The RealReal

Rackspace Technology, Inc.

TFF Pharmaceuticals

Engaging in the world of low-cost stocks often referred to as penny stocks, is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk.

10 Top Penny Stocks To Buy According To Insiders In August

Investing in penny stocks represents an enticing prospect for those seeking to leverage the stock market's potential gains. Characterized by an inherent risk and the promise of significant rewards, these under-$5 shares often become the subjects of speculation.

7 Penny Stocks To Buy According To Insiders In August

Penny stocks provide a captivating opportunity for those aiming to profit in the stock market. The intrinsic risk and potential rewards associated with these stocks often lead to intense speculation and a quest for remarkable profits.

4 Penny Stocks To Buy According To Insiders In August

Bioventus Inc. (NASDAQ:BVS ) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET Company Participants Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Robbie Marcus - JPMorgan Operator Thank you for standing by, and welcome to Bioventus, Inc. Second Quarter 2023 Earnings Conference Call. I will now turn the call over to your host for today, Mr.

Bioventus Inc. (BVS) Q2 2023 Earnings Call Transcript

DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023.

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

DURHAM, N.C., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will present at the Canaccord Genuity Global Growth Conference on Thursday, August 10, 2023, at 8:00 a.m. ET.

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

DURHAM, N.C., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market opens on Tuesday, August 8, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

Shares of medical device concern Bioventus Inc. have more than tripled off their May 4th intraday low as a decent Q1 2023 report and the return of its ex-CEO have provided confidence. That said, Bioventus stock is still off over 80% from its all-time high after an aggressive acquisition spree put the company in breach of certain covenants in its credit agreement. With one divestment in process, a just-completed restructuring, and continuing headwinds in its hyaluronic acid business, the recent insider buying merited a deeper dive into this busted IPO.

Bioventus: Return Of The King

DURHAM, N.C., May 23, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction, announced earlier this month, enables Bioventus' improved focus on execution and delivers approximately $30 million of net closing proceeds, which will be used for debt repayment.

Bioventus Completes Divestiture of its Wound Business

Canoo

NovaBay Pharmaceuticals

Understanding the stock market can be a challenging endeavor, yet it offers vast potential for substantial gains, particularly when it comes to penny stocks. Penny stocks, which typically trade below $5 per share, offer an accessible route to market participation, often piquing the interest of investors seeking higher returns with lower capital.

Looking for Undervalued Penny Stocks? Use These Tips

180 Life Sciences 

Take a look at these 3 industries to find penny stocks in.

Penny Stock Investing, 3 High-Growth Industries to Watch

Bioventus Inc. (NASDAQ:BVS ) Q1 2023 Earnings Conference Call May 16, 2023 5:00 PM ET Company Participants Dave Crawford - VP, IR Tony Bihl - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Kyle Rose - Canaccord Drew Ranieri - Morgan Stanley Operator Good afternoon, and welcome to the Bioventus Inc. First Quarter 2023 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Dave Crawford, Vice President, Investor Relations.

Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript

DURHAM, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023.

Bioventus Reports First Quarter Financial Results

DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will now report financial results for the first quarter of fiscal year 2023 after the market closes on Tuesday, May 16, 2023. The Company's management will host a conference call at 5:00 p.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today the Company plans to file Form 12b-25, Notification of Late Filing, for its Quarterly Report on Form 10-Q for the period ended April 1, 2023, on May 11, 2023.

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

DURHAM, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has signed a definitive agreement to sell its Wound business, including the skin substitutes TheraSkin and TheraGenesis, to LifeNet Health. The transaction includes a total cash consideration of $85 million, including $35 million in cash at close, a $5 million cash payment deferred 18 months, and $45 million in potential earn-out payments. At the time of close the Company expects to net approximately $30 million after fees and expenses which will be used to repay existing debt.

Bioventus Announces Divestiture of its Wound Business

DURHAM, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2023 before the market opens on Thursday, May 11, 2023. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

Bright Horizons Family Solutions

Earthstone Energy

BVS, BFAM and ESTE have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2023.

New Strong Sell Stocks for April 5th

DURHAM, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that Ken M. Reali has stepped down as Chief Executive Officer (CEO) and as a member of the Board of Directors (board). The board has initiated a comprehensive search process to identify a permanent CEO.

Bioventus Announces CEO Leadership Change

Bioventus Inc. (NASDAQ:BVS ) Q4 2022 Earnings Conference Call March 31, 2023 8:30 AM ET Company Participants Dave Crawford - Vice President, Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Caitlin Cronin - Canaccord Operator Good day. And welcome to the Bioventus Incorporated Fourth Quarter 2022 Earnings Conference Call.

Bioventus Inc. (BVS) Q4 2022 Earnings Call Transcript

DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the year ended December 31, 2022.

Bioventus Reports Fourth Quarter and Full-Year 2022 Financial Results

DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has entered into an Amendment No. 4 (the “Amendment”) to the Credit and Guaranty Agreement, between the Company, Wells Fargo Bank, National Association as Administrative Agent and Collateral Agent, and the Lenders from time to time party thereto, dated as of December 6, 2019 and as amended on August 29, 2021, October 29, 2021 and July 11, 2022 (the “Credit Agreement”).

News for Bioventus Stock (BVS)